A new trading day began on Monday, with Fate Therapeutics Inc (NASDAQ: FATE) stock price down -6.67% from the previous day of trading, before settling in for the closing price of $1.35. FATE’s price has ranged from $0.66 to $3.50 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -2.63% over the past five years. Meanwhile, its annual earnings per share averaged 28.76%. With a float of $109.59 million, this company’s outstanding shares have now reached $114.66 million.
Fate Therapeutics Inc (FATE) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 4.97%, while institutional ownership is 70.54%. The most recent insider transaction that took place on Aug 04 ’25, was worth 9,573. In this transaction an insider of this company sold 9,037 shares at a rate of $1.06, taking the stock ownership to the 397,670 shares. Before that another transaction happened on Aug 04 ’25, when Company’s President and CEO sold 14,466 for $1.06, making the entire transaction worth $15,396. This insider now owns 334,898 shares in total.
Fate Therapeutics Inc (FATE) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.4 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.53% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Here are Fate Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.19 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Fate Therapeutics Inc (NASDAQ: FATE) saw its 5-day average volume 1.62 million, a negative change from its year-to-date volume of 2.09 million. As of the previous 9 days, the stock’s Stochastic %D was 5.45%.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 33.98%, which indicates a significant increase from 4.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1594 in the past 14 days, which was higher than the 0.1030 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2217, while its 200-day Moving Average is $1.1690. Nevertheless, the first resistance level for the watch stands at $1.3633 in the near term. At $1.4667, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.5333. If the price goes on to break the first support level at $1.1933, it is likely to go to the next support level at $1.1267. The third support level lies at $1.0233 if the price breaches the second support level.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
With a market capitalization of 145.32 million, the company has a total of 115,330K Shares Outstanding. Currently, annual sales are 13,630 K while annual income is -186,260 K. The company’s previous quarter sales were 1,910 K while its latest quarter income was -34,070 K.
